ALKS Related Analyst Ratings
-
Leerink Swann Starts Alkermes (ALKS) at Outperform
-
UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
-
BofA/Merrill Lynch Downgrades Alkermes (ALKS) to Underperform
-
Lazard Capital Downgrades Alkermes (ALKS) to Neutral
-
Mizuho Securities Downgrades Alkermes (ALKS) to Neutral
-
BofA/Merrill Lynch Downgrades Alkermes (ALKS) to Neutral
-
MKM Partners Downgrades Alkermes (ALKS) to Neutral
-
Credit Suisse Starts Alkermes (ALKS) at Neutral
-
Morgan Stanley Upgrades Alkermes (ALKS) to Overweight
-
Morgan Stanley Starts Alkermes (ALKS) at Equalweight
-
Mizuho Securities Starts Alkermes (ALKS) at Buy
-
MKM Says Alkermes (ALKS) Quarter Positive, Notes Revenue Miss Timing-Related
-
Citi Starts Alkermes (ALKS) at Buy
-
Refinancing of Debt Helps Alkermes (ALKS) Save Cash, MKM Reiterates Buy, Raises PT
-
Baird Comments on Amylin (AMLN) On Takeover Speculation
-
Jefferies Reiterates a 'Buy' on Alkermes (ALKS); Elan Overhang Removed
-
Jefferies Raises Estimates & PT on Alkermes (ALKS); A Very Good Start Out of the Gates
-
Jefferies Maintains a 'Buy' on Alkermes (ALKS); Bydureon Approved; Not Another "Third Time's The Charm" Title
-
MKM Upgrades Alkermes (ALKS) to Buy, Raises Target to $20
-
Jefferies Comments on Alkermes (ALKS) Partnership Spilt with Eli Lilly (LLY) and Amylin (AMLN)
-
MKM Cuts Alkermes (ALKS) to Neutral
-
Jefferies Assumes Alkermes (ALKS) at Buy
-
Goldman Raises Price Target on Alkermes (ALKS) Following Close of Elan Drug Merger
-
Jefferies Comments on Elan Corp (ELN), Making Moves in The Right Direction
-
Caris & Co. Upgrades Alkermes (ALKS) to Buy
-
UPDATE - UBS Upgraded Alkermes (ALKS) to Buy; Compelling Story at Current Levels
-
UBS Upgrades Alkermes (ALKS) to Buy
-
Lazard Capital Upgrades Alkermes (ALKS) to Buy
-
UBS Maintains a 'Neutral' on Alkermes (ALKS); Bydureon Passes the tQTc Test
-
MKM Partners Starts Alkermes (ALKS) at Buy
-
UBS Maintains a 'Neutral' on Alkermes (ALKS); Bigger, Faster, Stronger
-
Jefferies Raises Price Target on Alkermes (ALKS), Looking Towards the Future And Things Look Good
-
Caris & Co. Downgrades Alkermes (ALKS) to Average
-
Cowen Upgrades Alkermes (ALKS) to Outperform
-
UPDATE: Leerink Leerink Swann Upgraded Alkermes (ALKS) to Outperform, Raises Valuation Range to $16-$19
-
UBS Maintains a 'Neutral' on Alkermes (ALKS); Scaling Up and Diversifying
-
Leerink Swann Upgrades Alkermes (ALKS) to Outperform
-
Alkermes (ALKS) Shares Rising as BofA Merrill Adds to US 1 List
-
Goldman Sachs Starts Alkermes (ALKS) at Neutral
-
Jefferies Changes Estimates & Raises Price Target on Alkermes (ALKS), Maintains Hold Rating
-
Caris & Co. Upgrades Alkermes (ALKS) to Above Average
-
UPDATE - UBS Downgrades Alkermes (ALKS) to Neutral; Bydureon’s Delay Puts Overhang on Shares
-
UBS Downgrades Alkermes (ALKS) to Neutral
-
Wave of Downgrades Hits Amylin, Alkermes, Eli Lilly (AMLN, ALKS, LLY)
-
Jefferies Downgrades Alkermes (ALKS) to Hold
-
UBS Initiates Coverage on Alkermes (ALKS) with a Buy; Finally Ready to Breakout?
-
UBS Starts Alkermes (ALKS), Par Pharma (PRX) at Buy, Salix Pharma (SLXP) at Neutral
-
Caris & Co Initiates Coverage Biotechnology and Drug Stocks AMLN & ALKS
-
Jesup & Lamont Initiates Coverage on Alkermes (ALKS) with a Buy
-
Hapoalim Securities Upgrades Alkermes (ALKS) to Buy
Back to ALKS Stock Lookup
